Lund, Sweden — 30 December 2022 — During December 2022, 39,596 subscription warrants in Camurus’ subscription warrant series TO2019/2022 have been exercised and as a consequence the number of shares and votes has increased by 39,596.
Prior to the exercise, the total number of shares in Camurus amounted to 55,383,447, corresponding to 55,383,447 votes. As of 30 December 2022, the total number of shares in Camurus amounts to 55,423,043 corresponding to 55,423,043 votes.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
The information is such that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication on 30 December 2022 at 7.00 am CET.